Japan's Shionogi Sues Sawai, Claiming Patent Violation For Antibiotic
This article was originally published in PharmAsia News
Executive Summary
Two Japanese pharmaceutical companies are headed for court over a generic version of a branded biotic drug. Shionogi has sued Sawai Pharmaceutical, saying it violated the plaintiff's patent for the crystallization technique used in making Flomox (cefcapene). Shionogi's cefcapene patent expired last October and Sawai began marketing a generic of it in May. Shionogi said its crystallization patent, however, remains effective through March 2011, and that Sawai's generic violates it. (Click here for more - a subscription may be required
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.